Andrew Ferguson, FTC chair (Photo by Samuel Corum/Sipa USA)
Teva, Novartis get fresh warnings from FTC over Orange Book patent listings
The FTC is continuing its campaign against drug patents that it claims are improperly listed in an FDA database known as the Orange Book, carrying …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
